PAHC · Company research
Phibro Animal Health Corporation Class A (PAHC): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
37records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| PAHC Nov 2026 17.500 put (PAHC261120P00017500) Stock Price, News, Quote & History - Yahoo! Finance Canada | PAHC Nov 2026 17.500 put (PAHC261120P00017500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| PAHC Nov 2026 35.000 put (PAHC261120P00035000) Stock Price, News, Quote & History - Yahoo! Finance Canada | PAHC Nov 2026 35.000 put (PAHC261120P00035000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 17, 2026 | neutral | 0 | 0.6 |
| Reasons to Add STE Stock to Your Portfolio Right Now | STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| Haemonetics Gains 149.3% in a Year: What's Driving the Rally? | Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Reasons to Add STE Stock to Your Portfolio Right Now | STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| Haemonetics Gains 149.3% in a Year: What's Driving the Rally? | Haemonetics shares surged 149.3% over the past year, significantly outperforming the industry and S&P 500. The company's Plasma and MedSurg segments showed solid growth in Q1 fiscal 2027, with Plasma revenues up 7.2% and MedSurg up 6%. HAE raised its fiscal 2027 revenue guidance to 5-8%, but faces headwinds from high debt levels ($1.17 billion long-term debt) and competitive pressures. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Is it Apt to Retain Medtronic Stock in Your Portfolio Now? | Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| Is it Apt to Retain Medtronic Stock in Your Portfolio Now? | Medtronic is expanding its presence in high-growth markets including cardiac ablation (up 88%), robotics, and structural heart, while advancing the MiniMed separation. The company is building its hypertension business through the Symplicity Spyral renal denervation franchise with improved reimbursement and clinical evidence. However, Medtronic faces headwinds from tariffs, inflation, currency fluctuations, and unfavorable product mix that could pressure margins. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.75 | 1 |
| PAHC Oct 2026 45.000 call (PAHC261016C00045000) Interactive Stock Chart - Yahoo! Finance Canada | PAHC Oct 2026 45.000 call (PAHC261016C00045000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| PAHC Oct 2026 30.000 call (PAHC261016C00030000) Stock Price, News, Quote & History - Yahoo! Finance Canada | PAHC Oct 2026 30.000 call (PAHC261016C00030000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| PAHC Dec 2026 20.000 put (PAHC261218P00020000) Interactive Stock Chart - Yahoo! Finance Canada | PAHC Dec 2026 20.000 put (PAHC261218P00020000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? | Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| Is it Apt to Retain Prestige Consumer Stock in Your Portfolio Now? | Prestige Consumer Healthcare (PBH) is building its consumer health brand portfolio through strategic acquisitions of Breathe Right and LaCorium, expected to contribute $190 million in fiscal 2027 revenues. The company benefits from strong e-commerce growth at double-digit rates and brand-building initiatives across established franchises. However, intense competition, pricing pressure, and foreign exchange fluctuations pose ongoing challenges. PBH holds a Zacks Rank #3 (Hold) rating with an earnings yield of 9.4%, outpacing the industry average. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.75 | 1 |
| PAHC Dec 2026 50.000 call (PAHC261218C00050000) Stock Price, News, Quote & History - Yahoo! Finance Canada | PAHC Dec 2026 50.000 call (PAHC261218C00050000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Phibro Animal Health Corporatio (PAHC) Stock Forecasts - Yahoo Finance | Phibro Animal Health Corporatio (PAHC) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Trading Systems Reacting to (PAHC) Volatility - Stock Traders Daily | Trading Systems Reacting to (PAHC) Volatility Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 13, 2026 | neutral | 0 | 0.6 |
| Is it the Right Time to Hold TNDM Stock in Your Portfolio? | Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| Is it the Right Time to Hold TNDM Stock in Your Portfolio? | Tandem Diabetes Care (TNDM) is expanding its product portfolio with new tubeless pump technology and next-generation closed-loop systems while driving international sales growth through direct commercialization. However, the company faces headwinds from intense competitive pressure, GLP-1 drug adoption impacts on insulin therapy demand, and supply chain constraints that are expected to persist through 2026. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.75 | 1 |
| What Is Drawing Attention To Phibro Animal Health (PAHC) Today? - Yahoo Finance | What Is Drawing Attention To Phibro Animal Health (PAHC) Today? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Phibro Animal Health Corporatio (PAHC) Stock Forecasts - Yahoo Finance | Phibro Animal Health Corporatio (PAHC) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 9, 2026 | neutral | 0 | 0.6 |
| Is it the Right Time to Add Phibro Stock to Your Portfolio? | Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Is it the Right Time to Add Phibro Stock to Your Portfolio? | Phibro Animal Health (PAHC) is gaining momentum from strong Animal Health segment growth, driven by the Zoetis MFA acquisition, vaccine expansion, and mineral nutrition demand recovery. However, the company faces headwinds from macroeconomic risks, trade policy uncertainties, and foreign exchange volatility that continue to pressure reported results. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.6 | 1 |
| Is it the Right Time to Add Phibro Stock to Your Portfolio? - Yahoo Finance | Is it the Right Time to Add Phibro Stock to Your Portfolio? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Encompass Health Expands Rehab Footprint With New Maine Hospital | Encompass Health Corporation (EHC) opened its first wholly owned hospital in Maine with 50 inpatient rehabilitation beds. Q2 2026 discharges rose 5.6% year-over-year, driven by new capacity and 2.8% same-store growth. EHC opened three hospitals in the first half of 2026 and plans to open eight new hospitals throughout the year, reflecting its strategy to expand capacity in favorable markets. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Is This the Right Time to Add TMO Stock to Your Portfolio? | Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| Is This the Right Time to Add TMO Stock to Your Portfolio? | Thermo Fisher Scientific (TMO) is strengthening growth through innovation, AI investments, and strategic acquisitions expected to contribute $1.6 billion in revenues and 32 cents to adjusted EPS in 2026. The company expects organic revenue growth at 3%-4% for 2026 supported by broad-based end-market improvements. However, risks from macroeconomic uncertainty, inflation, geopolitical disruption, and unfavorable currency movements could weigh on results and margins. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 1 | 1 |
| PAHC vs. HAE: Which Stock Is the Better Value Option? - Yahoo Finance | PAHC vs. HAE: Which Stock Is the Better Value Option? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| Neogen Stock Rallies 83% YTD: What's Driving the Surge? | Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Neogen Stock Rallies 83% YTD: What's Driving the Surge? | Neogen (NEOG) shares have surged 83% year-to-date, outperforming the S&P 500, driven by strong Food Safety segment growth with core revenue increases of 5.8% in Q4 fiscal 2026. The company is expanding manufacturing capabilities following its 3M Food Safety acquisition, planning a 50% increase in R&D spending for fiscal 2027 focused on pathogen detection and sanitation platforms. However, fiscal 2027 EPS is projected to decline 3.1% before recovering with 17.2% growth in fiscal 2028. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 1 | 1 |
| Phibro Animal Health (NasdaqGM:PAHC) Stock Forecast & Analyst Predictions - Simply Wall Street | Phibro Animal Health (NasdaqGM:PAHC) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Sep 25, 2026 | neutral | 0 | 0.6 |
| Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report? - Yahoo Finance | Why Is Phibro (PAHC) Down 6.7% Since Last Earnings Report? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| Phibro Animal Health (PAHC): Buy, Sell, or Hold Post Q2 Earnings? - Yahoo Finance | Phibro Animal Health (PAHC): Buy, Sell, or Hold Post Q2 Earnings? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars - StockStory | Phibro Animal Health (NASDAQ:PAHC) Reports Strong Q2 CY2026, Stock Soars StockStory | View source ↗ | StockStory | Aug 26, 2026 | neutral | 0 | 0.6 |
| Should You Continue to Retain PAHC Stock in Your Portfolio? - Yahoo Finance | Should You Continue to Retain PAHC Stock in Your Portfolio? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 19, 2026 | neutral | 0 | 0.6 |
| Should Value Investors Buy Phibro Animal Health (PAHC) Stock? - Yahoo Finance | Should Value Investors Buy Phibro Animal Health (PAHC) Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 6, 2026 | neutral | 0 | 0.6 |
| Should You Continue to Hold PAHC Stock in Your Portfolio? - Yahoo Finance | Should You Continue to Hold PAHC Stock in Your Portfolio? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 15, 2026 | neutral | 0 | 0.6 |
| PAHC Stock Falls Despite Q3 Earnings & Revenue Beat, Margins Rise - Yahoo Finance | PAHC Stock Falls Despite Q3 Earnings & Revenue Beat, Margins Rise Yahoo Finance | View source ↗ | Yahoo Finance | May 8, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.